Adaptive Biotechnologies (ADPT) Debt to Equity (2022 - 2026)

Adaptive Biotechnologies has disclosed Debt to Equity across 5 years of filings, most recently posting $0.6 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.6, down 14.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.6 (down 14.05% YoY), and the FY2025 annual result was $0.6, down 8.89% from the prior year.
• Debt to Equity came in at $0.6 for Q1 2026 at Adaptive Biotechnologies, up from $0.6 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.74 in Q2 2025 to a low of $0.27 in Q4 2022.
• The 5-year median for Debt to Equity is $0.6 (2024), against an average of $0.55.
• Across the five-year window, Debt to Equity jumped 65.21% in 2024 and declined 14.05% in 2026, its largest moves.
• Adaptive Biotechnologies' Debt to Equity stood at $0.27 in 2022, then surged by 56.91% to $0.42 in 2023, then soared by 55.3% to $0.66 in 2024, then decreased by 8.89% to $0.6 in 2025, then climbed by 0.63% to $0.6 in 2026.
• The last three Debt to Equity figures came in at $0.6 (Q1 2026), $0.6 (Q4 2025), and $0.64 (Q3 2025), per Business Quant data.